HUTCHMED DRC shares moved higher in morning trading, rising 2.3% following the company's announcement that full Phase III findings for sovleplenib were presented at the European Hematology Association Congress in Stockholm, Sweden on June 11, 2026. The ESLIM-02 study enrolled 90 adult Chinese patients with warm antibody autoimmune hemolytic anemia - each of whom had relapsed or were refractory to at least one prior standard treatment. The trial met its primary endpoint, delivering a durable hemoglobin response rate of 66% for patients treated with sovleplenib during weeks 5 through 24, compared with a 15% response rate for placebo.
The clinical result addresses a disease area that currently lacks any approved targeted therapies, and the magnitude of the difference between active treatment and placebo was described as statistically striking in the company announcement. Investors reacted to the clear efficacy signal and the potential therapeutic significance of the outcome, pushing the stock higher during the session.
Regulatory developments amplified the market response. China’s National Medical Products Administration has accepted HUTCHMED’s New Drug Application for sovleplenib in warm antibody autoimmune hemolytic anemia and assigned it priority review status in April 2026. In addition, the therapy received Breakthrough Therapy Designation in March 2026. HUTCHMED retains all worldwide rights to sovleplenib, meaning any future approvals would be wholly attributable to the company. The drug is also undergoing priority NDA review in China for immune thrombocytopenia, broadening the near-term regulatory and commercial opportunity described by the company.
Market conditions provided a neutral-to-supportive backdrop to HUTCHMED’s outperformance. On the day, the S&P 500 edged up +0.2%, the Dow Jones Industrial Average added +0.4%, and the NASDAQ was essentially flat at +0.0%. With no major macroeconomic releases or Federal Reserve announcements identified as material drivers for the session, company-specific developments drove trading in HUTCHMED shares.
By midmorning, the stock was moving toward $10.92, reflecting renewed investor confidence, though it remained below its 52-week high of $19.50. The share-price response combined the strong Phase III efficacy data, the active regulatory review process, and HUTCHMED’s exclusive global ownership of sovleplenib as the principal reasons behind the market’s positive reaction.
Summary
HUTCHMED reported full Phase III data for sovleplenib presented at a June 11, 2026 conference, showing a 66% durable hemoglobin response rate versus 15% with placebo in 90 Chinese adults with relapsed or refractory warm antibody autoimmune hemolytic anemia. The drug has priority regulatory review and Breakthrough Therapy Designation in China, and HUTCHMED retains worldwide rights. The stock rose 2.3% in morning trading as investors digested the results and the regulatory status.
Key points
- ESLIM-02 Phase III met its primary endpoint - 66% durable hemoglobin response for sovleplenib versus 15% for placebo during weeks 5-24.
- Regulatory momentum in China - NDA accepted with priority review in April 2026 and Breakthrough Therapy Designation granted in March 2026; additional priority NDA review for immune thrombocytopenia is underway.
- Company retains all global rights to sovleplenib, concentrating commercial value within HUTCHMED.
Risks and uncertainties
- Regulatory risk - priority review and Breakthrough Designation do not guarantee approval; outcomes of the ongoing regulatory processes remain uncertain.
- Commercialization and market risk - while HUTCHMED holds worldwide rights, realizing commercial potential depends on successful regulatory approvals and subsequent market uptake.
- Stock valuation volatility - share price movement reflects investor reaction to a single clinical readout and regulatory milestones, and the stock remains below its 52-week high.
The convergence of a strong Phase III result, an active regulatory pathway in China, and HUTCHMED’s exclusive ownership of the asset provided the market with tangible reasons to reprice the stock upward during the session. The company-specific news dominated trading, as broader U.S. indices were largely steady.